Lumpectomy surgery for large ductal carcinoma in situ

被引:0
作者
Padilla, Daniela Bresciani [1 ]
Tsai, Jacqueline [1 ]
Beck, Amanda Sutherland [1 ]
Wapnir, Irene L. [2 ]
机构
[1] Stanford Univ, Dept Surg, Sch Med, Stanford, CA USA
[2] Stanford Univ, Dept Surg, Sch Med, 300 Pasteur Dr H3625, Stanford, CA 94305 USA
关键词
Ductal carcinoma in situ; Lumpectomy; Mastectomy; INTRADUCTAL BREAST-CANCER; SURGICAL ADJUVANT BREAST; PHASE-III; RADIOTHERAPY; MANAGEMENT; TAMOXIFEN; TRIAL;
D O I
10.1007/s10549-025-07621-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Breast-conserving surgery for larger ductal carcinoma in situ (DCIS) remains limited. We compare the attempted use and success rates of lumpectomy surgery in patients with DCIS measuring >= 4 cm versus < 4 cm. Methods A retrospective review was conducted using the institutional tumor registry to identify cases of pure DCIS that were surgically treated from 2015 to 2022. Clinical-pathological data were abstracted from electronic medical records. Pathologic tumor size on initial surgery was used to define the two cohorts. Comparisons of variables were made using Chi-square and ANOVA tests. Results A total of 669 patients, 84% (562) with tumors measuring < 4 cm and 16% (107) >= 4 cm were identified. Lumpectomy was the initial surgery performed for 89% of women with lesions measuring < 4 cm on preoperative imaging studies compared to 64% of those >= 4 cm. Overall, 461 (92.9%) of 496 in the < 4 cm succeeded at lumpectomy compared to 36 (56.3%) of 64 in the >= 4 cm group. Re-excision lumpectomies or mastectomy were performed in 27% and 44% of the < 4 cm and >= 4 cm subgroups. Lumpectomy was achieved for 70% of women with tumors in the 4 to 5.9 cm range compared to 33% in the 6-7.9 cm and the >= 8 cm groups. There were no local recurrences in the >= 4 cm group at an average of 4.4 years follow-up. Conclusion Lumpectomy is a viable option for many patients with DCIS >= 4 cm, especially those measuring < 6 cm, though repeat re-excisions may be required after initial attempt.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 24 条
  • [1] [Anonymous], Clinical Practice Guidelines in Oncology (NCCN Guidelines)
  • [2] Variation in the management of ductal carcinoma in situ in the UK: Results of the Mammary Fold National Practice Survey
    Bathla, S.
    Fatayer, H.
    Sirianni, C.
    Ashken, L.
    Khan, S. Mansoor
    Hignett, S.
    Rathinaezhil, R.
    Thomas, H.
    Isherwood, J.
    Topps, A.
    Waterworth, A.
    Glassman, D.
    Hunt, R.
    Mazari, F. A. K.
    McEvoy, K.
    Hoar, F.
    Graja, T.
    Youssef, M.
    Turner, E. J. H.
    Johnson, R.
    Kallaway, C.
    Zeidan, B.
    Almerie, M. Q.
    Cocker, D.
    O'Brien, J.
    Saha, S.
    Westbroek, D.
    Lee, C.
    Potter, S.
    Frank, L.
    Williams, K.
    Segaran, A.
    Elfadl, D.
    Ralph, J.
    Jones, R. M.
    Crosbie
    Ashken, L.
    Foulkes, R.
    Chand, N.
    Potter, S.
    Khan, A.
    Ledwidge, S.
    Tang, S.
    Ismail, W.
    Hamilton-Burke, W.
    Ives, C.
    Singh, J.
    Aggarwal, S.
    Irwin, G. W.
    Rattay, T.
    [J]. EJSO, 2016, 42 (08): : 1153 - 1161
  • [3] Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
    Cuzick, Jack
    Sestak, Ivana
    Pinder, Sarah E.
    Ellis, Ian O.
    Forsyth, Sharon
    Bundred, Nigel J.
    Forbes, John F.
    Bishop, Hugh
    Fentiman, Ian S.
    George, William D.
    [J]. LANCET ONCOLOGY, 2011, 12 (01) : 21 - 29
  • [4] Factors influencing surgical treatment decisions for breast cancer: a qualitative exploration of surgeon and patient perspectives
    Dicks, E.
    Roome, R.
    Chafe, J.
    Powell, E.
    McCrate, F.
    Simmonds, C.
    Etchegary, H.
    [J]. CURRENT ONCOLOGY, 2019, 26 (02) : E216 - E225
  • [5] Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study
    Elshof, Lotte E.
    Tryfonidis, Konstantinos
    Slaets, Leen
    van Leeuwen-Stok, A. Elise
    Skinner, Victoria P.
    Dif, Nicolas
    Pijnappel, Ruud M.
    Bijker, Nina
    Rutgers, Emiel J. Th.
    Wesseling, Jelle
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (12) : 1497 - 1510
  • [6] Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
    Fisher, B
    Dignam, J
    Wolmark, N
    Wickerham, DL
    Fisher, ER
    Mamounas, E
    Smith, R
    Begovic, M
    Dimitrov, NV
    Margolese, RG
    Kardinal, CG
    Kavanah, MT
    Fehrenbacher, L
    Oishi, RH
    [J]. LANCET, 1999, 353 (9169) : 1993 - 2000
  • [7] Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from national surgical adjuvant breast and bowel project B-17
    Fisher, B
    Dignam, J
    Wolmark, N
    Mamounas, E
    Costantino, J
    Poller, W
    Fisher, ER
    Wickerham, DL
    Deutsch, M
    Margolese, R
    Dimitrov, N
    Kavanah, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 441 - 452
  • [8] Addressing overtreatment of screen detected DCIS; the LORIS trial
    Francis, Adele
    Thomas, Jeremy
    Fallowfield, Lesley
    Wallis, Matthew
    Bartlett, John M. S.
    Brookes, Cassandra
    Roberts, Tracy
    Pirrie, Sarah
    Gaunt, Claire
    Young, Jennie
    Billingham, Lucinda
    Dodwell, David
    Hanby, Andrew
    Pinder, Sarah E.
    Evans, Andrew
    Reed, Malcolm
    Jenkins, Valerie
    Matthews, Lucy
    Wilcox, Maggie
    Fairbrother, Patricia
    Bowden, Sarah
    Rea, Daniel
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (16) : 2296 - 2303
  • [9] Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm
    Hamilton, Sarah Nicole
    Nichol, Alan
    Wai, Elaine
    Gondara, Lovedeep
    Garcia, Hector A. Velasquez
    Speers, Caroline
    Diocee, Rekha
    Truong, Pauline
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (02): : 381 - 388
  • [10] The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)
    Hwang, E. Shelley
    Hyslop, Terry
    Lynch, Thomas
    Frank, Elizabeth
    Pinto, Donna
    Basila, Desiree
    Collyar, Deborah
    Bennett, Antonia
    Kaplan, Celia
    Rosenberg, Shoshana
    Thompson, Alastair
    Weiss, Anna
    Partridge, Ann
    [J]. BMJ OPEN, 2019, 9 (03): : e026797